Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation

Oncogene volume 18, pages 5806–5813 (1999)Cite this article

Abstract

Activator protein 1 (AP-1) transactivation and ornithine decarboxylase (ODC) activity have been established as essential downstream effectors of mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA). Previous studies have shown that inhibition of either AP-1 transactivation or ODC activity suppressed tumor promoter-induced transformation. By utilizing the JB6 mouse epidermal cell system, the present study determined whether TPA-induced ODC gene expression and activity is independent of AP-1 transactivation. In three independent JB6 (P+) clones, stably expressing dominant negative c-jun, TPA-induced ODC gene expression and activity were similar compared to JB6 P+ cells expressing vector-control alone, while AP-1-dependent transcription was inhibited. Transformation-insensitive JB6 (P−) cells, which lack TPA-inducible c-jun expression, also exhibited similar induction of ODC activity by TPA. α-Difluoromethylornithine, an irreversible inhibitor of ODC, attenuated, at an equivalent IC50, both TPA-induced ODC activity and anchorage-independent growth of JB6 P+ cells, despite no inhibition of AP-1 transactivation. Taken together, the results presented indicate that TPA-induced ODC gene expression and activity are independent of AP-1 transactivation. Because inhibition of either AP-1 or ODC precludes TPA-induced transformation, and because ODC is independent of AP-1, we propose that there are at least two pathways to transformation. Each pathway is required but not sufficient for transformation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

Abbreviations

TPA:

12-O-tetradecanoylphorbol-13-acetate

DFMO:

α-difluoromethylornithine

ODC:

ornithine decarboxylase

PKC:

protein kinase C

References

  • Angel P, Imagawa M, Chiu P, Stein B, Imbra RJ, Hans RJ, Jonat C, Herrlich P and Karin M. . 1987 Cell 49: 729–739.

  • Ashendel CL, Staller JM and Boutwell RK. . 1983 Cancer Res. 43: 4327–4332.

  • Bello-Fernandez C, Packham G and Cleveland JL. . 1993 Proc. Natl. Acad. Sci. USA 90: 7804–7808.

  • Bernstein LR and Colburn NH. . 1989 Science 244: 566–569.

  • Boutwell RK. . 1974 CRC Crit. Rev. Toxicol. 2: 419–443.

  • Brown PH, Alani R, Preis LH, Szabo E and Birrer MJ. . 1993 Oncogene 8: 877–886.

  • Bush A, Mateyak M, Dugan K, Obaya A, Adachi S, Sedivy J and Cole M. . 1998 Genes Dev. 12: 3797–3802.

  • Carbone PP, Douglas JA, Larson PO, Verma AK, Blair IA, Pomplun M and Tutsch KD. . 1998 Cancer Epidemiol. Biomark. Prev. 7: 907–912.

  • Cmarik JL and Colburn NH. . 1997 In: Food Factors for Cancer Prevention. Ohigashi H, Osawa T, Terao J, Watanabe S and Yoshikawa T (eds).. Springer-Verlag: Tokyo pp. 67–76.

    Book  Google Scholar 

  • Colburn NH, Former BF, Nelson KA and Yuspa SH. . 1979 Nature 281: 589–591.

  • Colburn NH, Wendel E and Abruzzo G. . 1981 Proc. Natl. Acad. Sci. USA 78: 6912–6916.

  • Domann FE, Levy JP, Birrer MJ and Bowden GT. . 1994 Cell Growth Differ. 5: 9–16.

  • Dong Z, Birrer MJ, Watts RG, Matrisian LM and Colburn NH. . 1994 Proc. Natl. Acad. Sci. USA 91: 609–613.

  • Dong Z, Crawford HC, Lavrovsky V, Taub D, Watts R, Matrisian LM and Colburn NH. . 1997 Mol. Carc. 19: 204–212.

  • Driedger PE and Blumberg PM. . 1980 Proc. Natl. Acad. Sci. USA 77: 567–571.

  • Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harlev E, Graupner G, Lu XP and Pfahl M. . 1994 Nature 372: 107–111.

  • Furstenberger G, Kinzel V, Schwartz M and Marks F. . 1985 Science 230: 76–78.

  • Gilmour SK, Verma AK, Madara T and O'Brien TG. . 1987 Cancer Res. 47: 1221–1225.

  • Hsieh J-T, Denning MF, Heidel SM and Verma AK. . 1990 Cancer Res. 50: 2239–2244.

  • Huang C, Wei-Ya M, Young MR, Colburn N and Dong Z. . 1998 Proc. Natl. Acad. Sci. USA 95: 156–161.

  • Katz A and Kahana C. . 1987 Mol. Cell. Biol. 7: 2641–2643.

  • Kikkawa U, Takai Y, Tanaka Y, Miyake R and Nishizuka Y. . 1983 J. Biol. Chem. 258: 11442–11445.

  • Kim Y-J, Pan H and Verma AK. . 1994 Mol. Carc. 10: 169–179.

  • Lee H, Arsura M, Wu M, Duyao M, Buckler AJ and Sonenshein GE. . 1995 J. Expt. Med. 181: 1169–1177.

  • Li J-J, Dong Z, Dawson MI and Colburn NH. . 1996 Cancer Res. 56: 483–489.

  • Li J-J, Rhim JS, Schlegel R, Vousden KH and Colburn NH. . 1998 Oncogene 16: 2711–2721.

  • Love RR, Jacoby R, Newton MA, Tutsch KD, Simon K, Pomplun M and Verma AK. . 1998 Cancer Epidemiol. Biomark. Prev. 7: 989–992.

  • Lu L, Stanley BA and Pegg AE. . 1991 Biochem J. 277: 671–675.

  • Niedel JE, Kuhn LJ and Vandenbark GR. . 1983 Proc. Natl. Acad. Sci. USA 80: 36–40.

  • O'Brien TG, Megosh LC, Gilliard G and Soler AP. . 1997 Cancer Res. 57: 2630–2637.

  • Packham G and Cleveland JL. . 1997 Oncogene 15: 1219–1232.

  • Pegg AE. . 1986 Biochem. J. 234: 249–262.

  • Ray RM, Viar MJ, Patel TB and Johnson LR. . 1999 Am. J. Physiol. 276: G773–G780.

  • Reddig PJ, Kim Y-J and Verma AK. . 1996 Mol. Carc. 17: 92–104.

  • Slaga TJ, Budunova IV, Gimenez-Conti IB and Aldaz CM. . 1996 JID Symp. Proc. 1: 151–156.

  • Takigawa M, Verma AK, Simsiman RC and Boutwell RK. . 1982 Biochem. Biophys. Res. Comm. 105: 969–976.

  • Tseng C-P and Verma AK. . 1995 Mol. Cell. Biochem. 14: 7–12.

  • Verma AK and Boutwell RT. . 1980 Carcinogenesis 1: 271–276.

  • Verma AK. . 1992 In: Cellular and Molecular Targets of Chemoprevention. Steele VE, Stoner GD, Bone CW and Kelloff, GJ, (eds). CRC Press, Inc.: Florida pp. 207–224.

    Google Scholar 

  • Wagner AJ, Meyers C, Laimins LA and Hay N. . 1993 Cell Growth Differ. 4: 879–883.

  • Weeks CE, Herrmann AL, Nelson FR and Slaga TJ. . 1982 Proc. Natl. Acad. Sci. USA 79: 6028–6032.

Download references

Acknowledgements

This work was supported by the National Institutes of Health Grant, R01 CA42585.

Author information

Authors and Affiliations

  1. Department of Human Oncology, Medical School, University of Wisconsin, Madison, 53792, Wisconsin, WI, USA

    Aaron P Jansen & Ajit K Verma

  2. Laboratory of Biochemical Physiology, National Cancer Institute, Frederick, 21702, Maryland, MD, USA

    Nancy H Colburn

Authors
  1. Aaron P Jansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nancy H Colburn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ajit K Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jansen, A., Colburn, N. & Verma, A. Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation. Oncogene 18, 5806–5813 (1999). https://doi.org/10.1038/sj.onc.1202965

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202965

Keywords

This article is cited by

Search

Advanced search

Quick links